|
Defining nitrosamine acceptable intake based on technical feasibible limit rather than CPCA
|
|
6
|
501
|
February 11, 2024
|
|
N- nitroso Nitazoxanide
|
|
1
|
530
|
February 8, 2024
|
|
TGA (Australia) :australia: Updates Published Acceptable Intakes
|
|
3
|
873
|
February 7, 2024
|
|
Aromatic nitrogen "Is it possible for aromatic nitrogen to convert nitrosamine?"- Indole
|
|
10
|
2285
|
February 2, 2024
|
|
Nitrosamine Impurities in Topical Drug Product
|
|
3
|
628
|
February 3, 2024
|
|
N-nitroso Vonoprazan AI 96 ng/day- FDA
|
|
5
|
3631
|
January 29, 2024
|
|
Limit for NDSRI
|
|
3
|
1397
|
January 29, 2024
|
|
Updated EMA-Acceptable intakes (AIs) established for N-nitrosamines
|
|
20
|
5669
|
January 29, 2024
|
|
How to identify NDSRI for an API
|
|
5
|
789
|
January 24, 2024
|
|
The comprehensive prediction of carcinogenic potency and tumorigenic dose (TD50) for two problematic N-nitrosamines in food: NMAMPA and NMAMBA using toxicology in silico methods -Pub
|
|
0
|
284
|
January 23, 2024
|
|
A quick (dumb) question
|
|
10
|
1206
|
January 22, 2024
|
|
Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines
|
|
5
|
1290
|
January 11, 2024
|
|
Nitroso-melatonin
|
|
3
|
883
|
January 4, 2024
|
|
Calculation of allowable limit in drug product with two API's
|
|
3
|
899
|
January 4, 2024
|
|
AI limit for N-nitroso betahistine?
|
|
26
|
4020
|
January 4, 2024
|
|
NDSRI in metronidazole
|
|
1
|
840
|
December 28, 2023
|
|
What should be the AI for N-Nitrosamines where CPCA doesn't apply (e.g. N-Nitroso Pyrrole Analogues where alpha carbon directly double bonded to hetero atom)?
|
|
1
|
916
|
December 27, 2023
|
|
Calculation of Nitrosamines AI not covered by CPCA
|
|
3
|
1043
|
December 20, 2023
|
|
Australia TGA - postpone until end of Jun 2024 NTTP 37ng/day
|
|
0
|
512
|
December 15, 2023
|
|
Updated FDA list of published limits
|
|
15
|
4221
|
December 15, 2023
|
|
Nitrosamine due to preservative in ophthalmic
|
|
3
|
858
|
December 8, 2023
|
|
Control of NDSRIs impurity at Drug Substance (API) specification
|
|
8
|
1351
|
December 5, 2023
|
|
Differences of limit of EMA and FDA regulatory for category 1
|
|
0
|
579
|
November 23, 2023
|
|
CPCA Calculation System (Python Desktop)
|
|
1
|
1487
|
November 22, 2023
|
|
Use of the TD50 99 % CI for single dose rodent carcinogenicity studies -Pub
|
|
5
|
620
|
November 16, 2023
|
|
AI for NDSRIs with positive EAT and/or in-vivo mutagenicity study - FDA position?
|
|
2
|
663
|
November 9, 2023
|
|
N-Nitroso desmethyl bedaquiline
|
|
0
|
665
|
October 6, 2023
|
|
Nitrosamine in DS and DP specifications
|
|
2
|
854
|
September 20, 2023
|
|
N-nitroso-duloxetine
|
|
1
|
609
|
September 19, 2023
|
|
Nitrosamines without published AI, and possibly negative for carcinogenicity
|
|
9
|
1039
|
September 18, 2023
|